A5053203660- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Hematological disorders and diagnostics
- Acute Myeloid Leukemia Research
- Colorectal Cancer Treatments and Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Pharmacological Effects and Toxicity Studies
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Immune Response and Inflammation
- Sarcoma Diagnosis and Treatment
- Bacterial Identification and Susceptibility Testing
- Neuroscience and Neuropharmacology Research
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Erythrocyte Function and Pathophysiology
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcoholism and Thiamine Deficiency
University Hospital Cologne
2012-2024
LVR-Klinik Köln
2020
Centrum für Integrierte Onkologie
1986-2019
Praxis für Hämatologie und Onkologie
2007-2019
Ernst & Young (Israel)
2015
Krankenhaus Nordwest
2009
Justus-Liebig-Universität Gießen
1998
University of Cologne
1988
Intravenous (i.v.) iron can improve anaemia of chronic disease and response to erythropoiesis-stimulating agents (ESAs), but data on its use in practice without ESAs are limited. This study evaluated effectiveness tolerability ferric carboxymaltose (FCM) routine treatment anaemic cancer patients.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and clinically relevant side effect of chemotherapy. Approximately 50% all leukemia, lymphoma, colorectal- breast cancer patients are affected. CIPN induced by neurotoxic chemotherapeutic agents can manifest with sensory and/or motor deficits. It associated significant disability poor recovery. Common symptoms include pain, altered sensation, reduced or absent reflexes, muscle weakness, balance control insecure gait. These not...
Results of immunophenotypic examinations peripheral blood and/or bone marrow (BM), involved in low‐grade B‐cell non‐Hodgkin's lymphomas, were compared with the results cytomorphological and histopathological 133 adult patients. 69 cases chronic B‐lymphocytic leukaemia (B‐CLL), 16 centrocytic (CC) 14 centroblastic‐centrocytic (CB/CC) 15 immunocytomas (IC), 10 hairy cell (HCL), four prolymphocytic leukaemias (PLL), two B‐CLL transformation, one splenic lymphoma villous lymphocytes (SLVL),...
This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling. Adults stage IV expected receive two or more cycles myelosuppressive chemotherapy Hb less than equal 11.0 g/dL were randomized 2:1 blinded 500 μg every 3 weeks. The primary endpoint was OS; stratified Cox proportional hazards model used evaluate (upper confidence limit hazard ratio [HR] <...
STEINMETZ T., TOTZKE U., SCHWEIGERT M., MITTERMÜLLER J., NAWKA S., TESCH H., GROSCHEK SÖLING HELLEBRAND E. & TSAMALOUKAS A. (2010) European Journal of Cancer CareA prospective observational study anaemia management in cancer patients – results from the German Anaemia Registry The use erythropoiesis-stimulating agents (ESA) is still under debate. However, little known about rationales, strategies, objectives, and effectiveness treatments common practice. prospectively surveyed 2000 with...
4009 Background: FOLFIRINOX significantly increases survival in metastatic PC compared to gemcitabine, but its use is limited selected pts, due high toxicity. In the majority of cases, gemcitabine (gem) remains mainstay palliative treatment, although modest impact on and disease progression. The addition EGFR tyrosine kinase inhibitor erlotinib prolonged median for only 2 weeks.This study was aimed investigate effect adding Nimotuzumab (nimo), an anti-EGFR monoclonal antibody, first-line PC....
Multiple myeloma remains an incurable plasma cell malignancy which, despite improvements in overall survival over the last decade, is characterized by recurrent relapse and associated with a poor prognosis. This study investigates use of novel agents current real-world clinical practice management relapsed and/or refractory multiple (RRMM) Germany different lines therapy. A retrospective chart review was conducted for patients RRMM treated at centers across between May 2017 June 2018....
Abstract Objective. Treatment with erythropoiesis-stimulating factors (ESFs) can ameliorate anemia associated cancer and chemotherapy. However, half of anemic patients do not respond even to high doses. To determine that are predictive a treatment response, multicenter, prospective study was performed. Patients Methods. Investigated were baseline erythropoietin, reticulocytes soluble transferrin receptor (sTfR) after 2 weeks, hemoglobin 4 weeks. Anemic solid tumors received 150 μg/week...
Abstract The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of new comprehensive cytogenetic scoring system for MDS, chromosome 7 anomalies are no longer generally assigned to poor risk features but thoroughly separated. However, der(1;7)(q10;p10), hereinafter der(1;7), merged into group labeled “any other single” and belongs intermediate group, just by definition due lack adequate clinical data. aim our international...
The aim of this prospective cohort study was to assess current antianemic treatment cancer patients in German routine practice, including diagnostics, treatments, and quality life (QoL). 88 sites recruited 1018 at the start with hemoglobin (Hb) levels <11 g/dL (females) or <12 (males). Patients were followed up for 12 weeks. 63% had inoperable solid tumors, 22% operable 15% hematological malignancies. Over 85% received chemotherapy. Median age 67 years; 48% male. Red blood cell...
Objective: Given the safety concerns regarding off-label use of erythropoiesis-stimulating agents (ESAs) in treatment cancer-associated anemia, data from German Cancer Anemia Registry (CAR) were analyzed to examine whether current practice Germany adheres guidelines.Research design and methods: CAR was a web-based registry gathering patient for 12 weeks following anemia diagnosis or until primary objective achieved.Results: Of over 2000 patients surveyed, 783 treated with ESAs. Treatment...
Aims To assess the real-world healthcare resource utilization (HRU) and costs associated with different proteasome inhibitors (PIs) for treatment of patients relapsed and/or refractory multiple myeloma (RRMM) in Germany.Methods We conducted a retrospective medical chart review patterns, outcomes, HRU RRMM treated bortezomib, carfilzomib, or ixazomib second- third-line (2L 3L) therapy Germany. Data were collected between 1 January 2017 30 June 2017. Costs calculated based on drug prices unit...
A confocal laser scanning microscope (with a 543 nm laser) was used for imaging rat Purkinje cell dendritic spines at high 3-D resolution. In nutritionally controlled study of the rat, 5 months ethanol consumption demonstrated to alter dendrites in cerebellum. Intact showed significant elongation after exposure, whereas this neuromorphological alteration could not be detected controls. Spine regarded as compensative growth search new synaptic contacts due alcohol induced loss.
<b><i>Introduction:</i></b> Real-world data reflects treatments and outcomes in clinical practice contrast with controlled trials. This study evaluates real-life multiple myeloma (MM) patients receiving proteasome inhibitor (PI)-based the second or third therapy line 2017 Germany. <b><i>Methods:</i></b> is a retrospective chart review on adult relapsed/refractory MM treated ≥1 dose of PI-based regimen either therapy. Participating physicians...
Diagnostic results from cytomorphology and immunocytology of aspirated bone marrow (BM) were compared with the findings standard trephine histology 100 adult patients non‐leukaemic non‐Hodgkin's lymphomas (NHL) in a retrospective study. Immunocytological investigations performed by immunoenzymatic APAAP‐technique on BM smears monoclonal antibodies against CD19, CD3, CD10 or TdT antigens determination positive cells relation to total leucocytes. Corresponding obtained for combination 93/100...
Background: Anemia is a major cause of morbidity in cancer. Erythropoiesis stimulating agents (ESA) are mainstay treatment, although some patients lack response for unknown reasons. Recently, ESA dosing recommendations have changed and iron increasingly used as an adjunct. Due to these changes, potential laboratory predictors were re-evaluated.